Liposome as well as preparation method and application thereof

By encapsulating resimmonot and polypeptide drugs in liposomes, combining targeted liposomes with cancer cells, and induced pyrodynamic death using photodynamic therapy, the negative effects of chemotherapy drugs on normal tissues and resimmonotes are solved by encapsulating resimmonotes in liposomes, and combining targeted liposomes with cancer cells, and induced pyrodynamic death by using photodynamic therapy, the negative effects of The problem of local inflammation has achieved efficient treatment and immune response activation for breast cancer.

CN118975987APending Publication Date: 2024-11-19SOUTHERN MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411315646.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-20
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing chemotherapeutic drugs will have negative effects on normal tissues when treating cancer, and resimmonot is applied directly to the tumor and can easily cause local inflammation, and an effective combination method is lacking to improve treatment effect and reduce toxicity.

Method used

Develop a liposome containing resimmonot and polypeptide drugs, which utilizes the targeted properties of liposomes with overexpressing CD47 by encapsulating resimmonot and polypeptide drugs in a specific composition of liposomes. Cells bind and induce pyroptosis under light excitation, activate the anti-tumor immune response.

Benefits of technology

Selective aggregation and treatment of breast cancer cells is achieved, cell pyroptosis is induced through photodynamic therapy of polypeptide drugs, pro-inflammatory factors are released to improve tumor immunogenicity, and macrophage polarization is activated by resimilation to M1 type , enhance the anti-tumor immune response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118975987A_ABST
    Figure CN118975987A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a liposome as well as a preparation method and application thereof. The lipidosome comprises a lipidosome main body for encapsulating the rasimod and a polypeptide drug, the liposome main body comprises a first lipid, a second lipid and a block copolymer; the first lipid is 1, 2-dioleoyl lecithin, egg yolk lecithin, hydrogenated soybean lecithin, dipalmitic acid phosphatidylcholine or dioleoyl L alpha phosphatidyl ethanolamine; the second lipid is triglyceride, diglyceride or sterol; the block copolymer comprises a hydrophobic phospholipid and a hydrophilic long-chain polymer. The liposome provided by the invention can be used for preparing medicines for treating cancers.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceutical preparations, and specifically relates to a liposome and a preparation method and application thereof. Background Art

[0002] Cancer affects people all over the world; surgery, radiotherapy and chemotherapy are the most widely used treatments. Chemotherapeutic agents create conditions within cells that limit cell growth and replication, and cancer chemotherapy has made significant progress in recent years. Chemotherapeutic agents usually affect tumor cells and rapidly proliferating cells in normal tissues such as bone marrow, hair follicles and intestinal epithelium. Anorexia, nausea, vomiting, diarrhea, bone marrow suppression and alopecia are some of the negative effects commonly associated with chemotherapy. It would be advantageous to develop chemotherapeutic agents that provide effective anti-tumor therapy with minimal toxicity.

[0003] Liposomes are bilayer structures similar to cell membranes, mainly composed of phospholipids and cholesterol. Liposomes can be divided into three categories: small unilamellar liposomes with a particle size of 20-80nm; large unilamellar liposomes with a particle size of about 100-1000nm; and multilamellar liposomes with a particle size of about 1000-5000nm. Currently, the liposomes used in clinical practice are mainly ordinary liposomes (such as DaunoXome) and PEG-modified liposomes (such as Doxil).

[0004] There are many methods for preparing liposomes, which can be selected according to the properties or needs of the drug: (1) Thin film dispersion method: Dissolve phospholipids and other membrane materials in an appropriate amount of chloroform or other organic solvents. Lipid-soluble drugs can be added to the organic solvent, and then the solvent is removed under reduced pressure and rotation. After the lipid forms a thin film on the wall, add a buffer solution or other solution containing or without water-soluble drugs and shake it to form multilayer liposomes. (2) Injection method: Dissolve phospholipids and other lipid materials and lipid-soluble drugs in an organic solvent (oil phase), then inject the oil phase into the water phase (containing or not containing water-soluble drugs) at a uniform speed, and remove the organic solvent to obtain liposomes. Depending on the solvent, it can be divided into ethanol or tert-butyl alcohol injection method and ether injection method. (3) Reverse phase evaporation method: Dissolve phospholipids and other lipid materials in an organic solvent, such as chloroform, and then mix and emulsify with a drug-containing buffer in a certain proportion, and then evaporate the organic solvent under reduced pressure to form liposomes. This method is suitable for the preparation of liposomes of water-soluble drugs and macromolecular active substances, such as insulin, and can improve the encapsulation rate. In addition, there are freeze-drying and melting methods. The liposomes formed by the above five methods are mostly multi-chamber liposomes, which can be further dispersed by various mechanical methods to reduce the particle size and form small unilamellar liposomes: a) Ultrasonic method The obtained large multi-layer liposomes are treated with ultrasound by an ultrasonic instrument, and small unilamellar liposomes are obtained according to the intensity and duration of the ultrasound. b) Homogenization method The obtained large multi-layer liposomes are homogenized into liposomes with smaller particle sizes by a tissue crusher or a high-pressure homogenizer. c) Extrusion method After the obtained large multi-layer liposomes are continuously passed through a polycarbonate fiber membrane with a pore size of 1.0-0.05μm under high pressure, the size distribution of the liposomes tends to be uniform, and most of them are unilamellar liposomes.

[0005] Drugs designed and synthesized through peptide sequences can specifically target tumor cells and inhibit their growth. In addition, peptide drugs can inhibit tumor cells by binding to specific targets on the surface or inside the tumor cells, blocking the activity of signal transduction pathways or enzymes.

[0006] Resiquimod is a clinical drug with immunomodulatory effects, mainly used to treat skin lesions and enhance antiviral and anti-tumor immune responses; it enhances the immune system by activating Toll-like receptors (TLR7 and TLR8); Resiquimod is usually applied directly to the tumor site in clinical adjuvant therapy, which can easily cause local inflammation. Therefore, there is an urgent need for a method of combining liposomes, resiquimod and peptide drugs for use in drugs for the treatment of tumors. Summary of the invention

[0007] The purpose of the present invention is to provide a liposome and a preparation method and application thereof. The liposome can be used to prepare a drug for treating cancer.

[0008] According to a first aspect of the present invention, the present invention provides a liposome, wherein the liposome comprises a liposome body encapsulating resiquimod and a polypeptide drug; the liposome body comprises a first lipid, a second lipid and a block copolymer.

[0009] In one aspect of the present invention, the first lipid is DOPC (1,2-dioleoylphosphatidylcholine), EPC (egg yolk phosphatidylcholine), HSPC (hydrogenated soybean phosphatidylcholine), DPPC (dipalmitoylphosphatidylcholine) or DOPE (dioleoyl L-α-phosphatidylethanolamine).

[0010] In one aspect of the invention, the liposome bodies have an average particle size of 135-145 nm.

[0011] In one aspect of the invention, the liposome body has an aggregation index of 0.18-0.24.

[0012] In one aspect of the invention, the liposomes have an average particle size of 175-195 nm.

[0013] In one aspect of the invention, the liposomes have an aggregation index of 0.18-0.22.

[0014] In one aspect of the present invention, the first lipid is HSPC (hydrogenated soy lecithin).

[0015] In one aspect of the invention, the second lipid is a triglyceride, a diglyceride or a sterol.

[0016] In one aspect of the invention, the second lipid is cholesterol.

[0017] In one aspect of the present invention, the block copolymer comprises a hydrophobic phospholipid and a hydrophilic long-chain polymer.

[0018] In one aspect of the present invention, the hydrophobic phospholipid is distearyl phosphatidyl amide, and the hydrophilic long-chain polymer is poly (2-ethyl-2-oxazoline).

[0019] In one aspect of the present invention, the block copolymer is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(2-ethyl-2-oxazoline) 2000 , namely DSPE-PEOz 2000 .

[0020] In one aspect of the present invention, the block copolymer is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(2-ethyl-2-oxazoline) with a molecular weight of 2,000.

[0021] In one aspect of the present invention, the mass ratio of the first lipid, the second lipid, the block copolymer and resiquimod is 20-30:1-5:1-5:1-5.

[0022] In one aspect of the present invention, the mass ratio of the first lipid, the second lipid, the block copolymer and resiquimod is 22-28:2-3:2-3:2-4.

[0023] In one aspect of the present invention, the first lipid, the second lipid, and the block copolymer are HSPC (hydrogenated soybean lecithin), cholesterol, DSPE-PEOz, respectively. 2000 ; The mass ratio of HSPC (hydrogenated soy lecithin), cholesterol, DSPE-PEOz 2000 and resiquimod is 22-28:2-3:2-3:2-4.

[0024] In one aspect of the present invention, the HSPC (hydrogenated soybean lecithin), cholesterol, DSPE-PEOz 2000 The mass ratio of styrene and resimod is 25:2.5:2.5:3.

[0025] In one aspect of the present invention, the polypeptide drug comprises at least one targeting chimeric peptide.

[0026] In one aspect of the present invention, the targeting chimeric peptide at least comprises a CD47 targeting chimeric peptide.

[0027] In one aspect of the present invention, the targeting chimeric peptide comprises at least a CD47 targeting chimeric peptide having the following structural formula:

[0028]

[0029] The CD47 targeting chimeric peptide is an MRS17 chimeric peptide, which is composed of a palmitic acid (Pal) portion, a photosensitizer protoporphyrin IX (PpIX), a tetraarginine peptide fragment (RRRR) and a CD47 blocking peptide (WSMTWWNYW).

[0030] In one aspect of the present invention, the CD47 targeting chimeric peptide is bound to the liposome body via the palmitic acid (Pal) moiety it contains.

[0031] In one aspect of the present invention, in the liposome, the mass ratio of the resiquimod to the polypeptide drug is 0.5-3:1.

[0032] According to a second aspect of the present invention, the present invention provides a method for preparing liposomes, the method comprising the following steps:

[0033] Step 1: dissolving the first lipid, the second lipid, the block copolymer and resiquimod in a first organic solution, obtaining a liposome film by rotary evaporation, and drying the liposome film;

[0034] Step 2: adding water to the dried liposome film, hydrating at 60° C.-80° C. for 20-45 min, and then ultrasonicating and filtering to obtain a liposome body encapsulating resiquimod;

[0035] Step 3: dissolving the polypeptide drug in a second organic solution to obtain an organic solution containing the polypeptide drug;

[0036] Step 4: taking a portion of the organic solution containing the polypeptide drug, quickly dispersing it with water, and then dialyzing it to remove the second organic solution, and changing the water several times during the dialysis process to obtain an aqueous solution containing the polypeptide drug;

[0037] Step 5: adding the liposome body encapsulating resiquimod into water and stirring, and at the same time adding the aqueous solution containing the polypeptide drug at a slow rate to obtain the liposome;

[0038] Wherein, the first lipid is 1,2-dioleoyl phosphatidylcholine, egg yolk phosphatidylcholine, hydrogenated soybean phosphatidylcholine, dipalmitoyl phosphatidylcholine or dioleoyl L-α-phosphatidylethanolamine;

[0039] The second lipid is triglyceride, diglyceride or sterol;

[0040] The block copolymer comprises a hydrophobic phospholipid and a hydrophilic long-chain polymer.

[0041] In one aspect of the present invention, in the aforementioned method, the first organic solution is a mixed solution of chloroform and methanol.

[0042] In one aspect of the present invention, in the aforementioned method, the second organic solution is DMSO.

[0043] In one aspect of the present invention, in the aforementioned method, the second lipid is cholesterol.

[0044] In one aspect of the present invention, in the aforementioned method, the mass ratio of the first lipid, the second lipid, the block copolymer and resiquimod is 20-30:1-5:1-5:1-5.

[0045] In one aspect of the present invention, in the aforementioned method, the polypeptide drug comprises at least one targeting chimeric peptide, wherein the targeting chimeric peptide comprises at least a CD47 targeting chimeric peptide having the following structural formula:

[0046]

[0047] In one aspect of the present invention, in the aforementioned method, the hydrophobic phospholipid is distearyl phosphatidyl amide, and the hydrophilic long-chain polymer is poly (2-ethyl-2-oxazoline).

[0048] In one aspect of the present invention, in the aforementioned method, the mass ratio of the first lipid, the second lipid, the block copolymer and resiquimod is 22-28:2-3:2-3:2-4.

[0049] In one aspect of the present invention, in step 2, the ultrasonic power is 80-120 mW, and the ultrasonic time is 3-6 min.

[0050] In one aspect of the present invention, in step 2, filtration is performed by using a filter membrane with a pore size of 800 μm.

[0051] In one aspect of the present invention, in step 4, dialysis is performed by using a dialysis bag with a dialysis molecular weight of 3500Da; the dialysis time is 18-36h.

[0052] In one aspect of the present invention, in step 5, after all the aqueous solution containing the polypeptide drug is added, stirring is continued for 15-60 minutes to prepare the liposome.

[0053] In one aspect of the present invention, a method for preparing liposomes is provided, wherein the liposomes comprise a liposome body encapsulating resiquimod and a polypeptide drug; the preparation method comprises the following steps:

[0054] Step 1: Mix 25 mg of HSPC (hydrogenated soy lecithin), 2.5 mg of cholesterol, and 2.5 mg of DSPE-PEOz 2000 and 3 mg of resimod were dissolved in a mixed solution of chloroform / methanol, and then subjected to reduced pressure rotary evaporation to form a liposome film, which was dried in a vacuum drying oven for 2 h;

[0055] Step 2: Add 10 mL of water to the dried liposome film and hydrate at 75° C. for 30 min; then use an ultrasonicator with a power of 100 mW for 5 min, and then filter through an 800 μm filter membrane to obtain a liposome body encapsulating resiquimod.

[0056] Step 3: Dissolve the MRS17 chimeric peptide in DMSO to prepare a 50 mg / mL stock solution;

[0057] Step 4: Take 60 μL of the mother solution and add it to a 10 mL EP tube, quickly disperse it with water, and then dialyze it with a 3500 kDa dialysis bag for 24 hours to remove the DMSO; change the water several times during the process;

[0058] Step 5: dissolving the liposome body encapsulating resiquimod in water and stirring, and at the same time adding the aqueous solution containing the polypeptide drug at a slow rate, and after all the aqueous solution containing the polypeptide drug is added, stirring is continued for 30 minutes to obtain the liposome.

[0059] According to a second aspect of the present invention, a pharmaceutical preparation is provided, comprising the aforementioned liposome and one or more pharmaceutical excipients.

[0060] According to a third aspect of the present invention, provided is the use of the liposomes prepared by the aforementioned pharmaceutical preparation or the aforementioned method in the preparation of a drug for treating cancer.

[0061] In one aspect of the invention, the cancer is non-small cell lung cancer, colon cancer, breast cancer, gastric cancer, esophageal cancer, prostate cancer, leukemia, head and neck cancer, pancreatic cancer, multiple myeloma or liver cancer.

[0062] In one aspect of the invention, the cancer is breast cancer.

[0063] The beneficial effects of the present invention are:

[0064] The liposomes provided by the present invention can specifically bind to breast cancer cells that overexpress CD47 to achieve selective aggregation on tumor tissues; the polypeptide drug can be inserted into the plasma membrane of breast cancer cells, trigger photodynamic therapy (PDT) in situ, and induce cell pyroptosis under light excitation; at the same time, pyroptotic cells will release a large number of pro-inflammatory factors to improve the immunogenicity of the tumor and recruit a large number of macrophages; and the release of resiquimod can polarize the infiltrating macrophages to the M1 type, activating anti-tumor immunity. BRIEF DESCRIPTION OF THE DRAWINGS

[0065] In the accompanying drawings, "R@L" refers to the liposome body encapsulating resiquimod; "MRS17" is a simple CD47 targeting chimeric peptide; "R848" refers to simple resiquimod; "R@L-MRS17" refers to the liposome encapsulating resiquimod containing the MRS17 chimeric peptide prepared in Example 1; the Pal group refers to the palmitic acid (Pal) part of the MRS17 chimeric peptide; "L-MRS17" refers to the liposome containing the MRS17 chimeric peptide without encapsulating resiquimod; "αPD-L1" refers to the PD-L1 monoclonal antibody; "R@L-MRS17+αPD-L1" refers to the combination of the liposome encapsulating resiquimod containing the MRS17 chimeric peptide and the PD-L1 monoclonal antibody; in Figures 10 to 14 In the figure, G1 refers to the blank control group, G2 refers to R@L, G3 refers to L-MRS17, and G4 refers to R@L-MRS17.

[0066] Figure 1 It is a schematic diagram of the preparation process of Example 1.

[0067] Figure 2 TEM images of R@L-MRS17 prepared in Example 1 and R@L prepared in Comparative Example 1.

[0068] Figure 3 These are the Zeta potential images of R@L-MRS17 prepared in Example 1, R@L prepared in Comparative Example 1, and L-MRS17 prepared in Comparative Example 2.

[0069] Figure 4 This is an image of the particle size and aggregation index (PDI) of R@L-MRS17 prepared in Example 1 changing over time in ultrapure water.

[0070] Figure 5 This is an image of the particle size and aggregation index (PDI) of R@L-MRS17 prepared in Example 1 in serum changing over time.

[0071] Figure 6 These are the ultraviolet spectra of R848, MRS17, R@L-MRS17 prepared in Example 1, and R@L prepared in Comparative Example 1.

[0072] Figure 7 These are the values ​​of the particle size of R@L-MRS17 prepared in Example 1 at 0 h, 0.5 h, 2 h and 12 h when pH = 6.5.

[0073] Figure 8 This is an image of the cell membrane stained with DIO after the R@L-MRS17 prepared in Example 1 was incubated with cells at pH 6.5 for a specific period of time.

[0074] Fig. 9 This is an image of the cell membrane stained with DIO after the R@L-MRS17 prepared in Example 1 was incubated with cells at pH 7.4 for a specific period of time.

[0075] Fig.10 The images are obtained by detecting the ROS production of G1 to G4 using ABDA and DCF.

[0076] Fig.11 These are images of R@L-MRS17-mediated in vitro cell pyroptosis from G1 to G4.

[0077] Fig.12 are the ICD images of pyroptosis induction from G1 to G4.

[0078] Fig.13 This is a schematic diagram of CD80 presented on the cell membrane surface.

[0079] Fig.14 This is a schematic diagram of MHC-II presented on the cell membrane surface. DETAILED DESCRIPTION

[0080] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is only an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the invention of the present invention based on the disclosed content, and they should also fall within the scope of the present invention.

[0081] In the present invention, the MRS17 chimeric peptide is composed of a palmitic acid (Pal) portion, a photosensitizer protoporphyrin IX (PpIX), a tetraarginine peptide fragment (RRRR) and a CD47 blocking peptide (WSMTWWNYW), wherein protoporphyrin IX (PpIX) is the final intermediate in the heme biosynthesis pathway; in clinical practice, patients usually orally or topically apply 5-aminolevulinic acid (5-ALA), which is converted into PpIX in vivo and used to treat various cancers by photodynamic therapy; however, due to the extremely poor water solubility of PpIX itself and its high degree of aggregation in vivo, the PDT effect is poor and it is difficult to apply directly. Its chemical formula is as follows:

[0082]

[0083] In the present invention, the structural formula of Resiquimod is as follows:

[0084]

[0085] Resiquimod can boost the immune system by activating Toll-like receptors (TLR7 and TLR8).

[0086] The present invention is further described below by way of specific examples. The various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels unless otherwise specified. Unless otherwise specified, the contents described below are all weight contents. Unless otherwise specified, it is understood that the process is carried out at room temperature.

[0087] Example

[0088] In the embodiment, "R@L" refers to the liposome body encapsulating resiquimod obtained in step 2; "MRS17" is a simple CD47-targeted chimeric peptide; "R848" refers to simple resiquimod; "R@L-MRS17" refers to the finally prepared liposome encapsulating resiquimod containing the MRS17 chimeric peptide; the Pal group refers to the palmitic acid (Pal) portion of the MRS17 chimeric peptide; "L-MRS17" refers to the liposome containing the MRS17 chimeric peptide without encapsulating resiquimod.

[0089] Embodiment 1:

[0090] Embodiment 1 comprises the following steps:

[0091] The preparation process of Example 1 includes film formation and introduction of polypeptide drugs, such as Figure 1 The specific steps are as follows: weigh 25 mg HSPC, 2.5 mg cholesterol, DSPE-PEOz 2000 2.5mg, R848 3mg were dissolved in a mixed solution of chloroform / methanol, and a pear-shaped bottle was used for vacuum rotary evaporation to form a liposome film, which was dried in a vacuum drying oven for 2h. 10mL of ultrapure water was added and hydrated at 75°C for 30min. Then, 100mW power was used for ultrasound in an ultrasonic disruptor for 5min, and then filtered through an 800μm filter membrane to obtain R@L. MRS17 was weighed and dissolved in DMSO to prepare a 50mg / mL mother solution. 60μL of the mother solution was added to a 10mL EP tube, which was quickly dispersed with water, and then dialyzed with a 3500Da dialysis bag for 24h to remove the DMSO. The water was changed several times during the period. R@L was then placed in a round-bottom flask, stirred rapidly with a magnetic stirrer, and then the polypeptide aqueous solution was added dropwise to the flask at a very slow speed; after 30min, the targeted liposome R@L-MRS17 inserted with MRS17 was harvested.

[0092] Comparative Example 1

[0093] The preparation process of R@L is the same as that of Example 1.

[0094] Comparative Example 2

[0095] Preparation process of L-MRS17: R848 is not included in the formula, and the rest is the same as Example 1.

[0096] Experimental Example 1: Performance Characterization Test

[0097] The particle size and distribution of R@L and R@L-MRS17 were detected by DLS. The test results showed that R@L had a particle size of 140.84±1.57nm, R@L had an aggregation index (PDI) of 0.210±0.020, R@L-MRS17 had a particle size of 184.01±6.29nm, and R@L-MRS17 had an aggregation index (PDI) of 0.201±0.018; the particle size did not change significantly before and after the Pal group was inserted into the liposome; Figure 2 TEM images of R@L and R@L-MRS17 show that R@L and R@L-MRS17 are uniform spherical nanoparticles. The potentials of MRS17, R@L and R@L-MRS17 were further tested. Figure 3 As shown, due to the presence of phospholipids, R@L exhibits a strong negative charge, while after the introduction of peptides, the charge of R@L-MRS17 weakens. Figure 4 The image of the particle size and aggregation index (PDI) of R@L-MRS17 prepared in Example 1 in ultrapure water changing with time; Figure 5 The image of the particle size and aggregation index (PDI) of R@L-MRS17 prepared in Example 1 in serum changes over time; Figure 4 and Figure 5 As can be seen in DSPE-PEOz 2000 With a hydration shielding layer, R@L-MRS17 has good stability in water and serum. Figure 6 is the UV spectrum of R848, MRS17, R@L and R@L-MRS17, from Figure 6 As can be seen, R@L-MRS17 successfully encapsulated and assembled R848 and MRS17.

[0098] Experimental Example 2: Performance Characterization Test in Slightly Acidic Environment

[0099] The R@L-MRS17 prepared in Example 1 was placed in an environment with pH = 6.5. Figure 7 These are the particle size values ​​of R@L-MRS17 at 0h, 0.5h, 2h and 12h when pH = 6.5; it can be seen that with the increase of time, R@L-MRS17 gradually disintegrates in a slightly acidic environment, thereby releasing the drug.

[0100] Experimental Example 3: In vitro cell experiment

[0101] 3.1: Cytoplasmic membrane targeting

[0102] R@L-MRS17 was prepared in slightly acidic culture medium, and after incubation with cells for a specific time, the cell membrane was stained with DIO, such as Figure 8As shown; it can be seen that in a slightly acidic environment, R@L-MRS17 has a strong plasma membrane anchoring ability, and the colocalization coefficient with DIO reaches above 0.86; this proves the plasma membrane targeting mediated by the special peptide design of MRS17, thereby achieving plasma membrane-targeted PDT-induced pyroptosis.

[0103] 3.2: Cytotoxicity assay

[0104] exist Fig.10 In the experiment, G1 was the blank control group, G2 was R@L, G3 was L-MRS17, and G4 was R@L-MRS17. ABDA and DCF were used to detect the ROS production rate of R@L-MRS17. The results are shown in Figure 2. Fig.10 As shown in A and B in the figure, it can be seen that R@L-MRS17 can produce strong ROS in both aqueous solution and cells under light. The cytotoxicity of R@L-MRS17 was determined by MTT method, and the results are shown in Fig.10 As shown in C; it can be seen that high concentrations of drugs have almost no dark toxicity to cells. After excitation with light of a specific wavelength, the PDT of R@L-MRS17 shows a concentration-related effect on tumor inhibition. The anti-proliferation ability of drugs on cells was further explored through live / dead double staining experiments (D). Living cells are easily stained with Calcein-AM to show green fluorescence, while damaged cells may be penetrated by PI to show red fluorescence. After illumination, the red fluorescence of the group containing MRS17 is enhanced, and the strategy of targeted delivery of photosensitizers to the surface plasma membrane significantly enhances the PDT effect.

[0105] 3.3: R@L-MRS17-mediated pyroptosis in vitro

[0106] like Fig.11 As shown in the figure, CD47 targeting peptide-mediated cell membrane targeting, Pal and PpIX-mediated hydrophobic interaction insertion, and tetra-arginine fragment-mediated electrostatic adsorption enable MRS17 to be targeted to the plasma membrane. The ROS generated after PDT destroys the stability of the cell membrane and causes the cell membrane to swell and rupture ( Fig.11 As shown in A in the figure), pyroptosis was induced. Through WB experiment (protein was extracted after drug treatment, and protein blot was developed by electrophoresis and antibody binding), it was observed that ( Fig.11 As shown in Figure B), the high concentration of ROS generated by plasma membrane-targeted PDT causes Cas-1 to be cut, which in turn leads to the cleavage of GSDMD and the release of the GSDMD-N domain. GSDME-N translocates to the cell membrane and forms membrane pores, driving cell swelling, membrane rupture, and the release of DAMPs, leading to pyroptosis-induced immune responses.

[0107] 3.4: Pyroptosis-induced ICD

[0108] PDT is based on the principle of inducing pyroptosis and tissue destruction by generating cytotoxic ROS under light activation of photosensitizers. Pyroptosis is a newly identified form of ICD mediated by gasdermin family proteins with an N-terminal domain and a C-terminal inhibitory domain, and is associated with plasma membrane pore formation, cell swelling, and the release of multiple DAMPs induced by inflammatory responses. Pyroptosis promotes the release of DAMPs, such as the translocation of CRT to the surface of dying cells after endoplasmic reticulum stress, which can promote the phagocytosis of macrophages and immature dendritic cells into dead tumor cells and their fragments, as well as the extracellular release of HMGB1 to confer high immunogenicity to tumor cells.

[0109] The expression of CRT and HMGB1 was detected by immunofluorescence experiment, and the subcellular localization of CRT and HMGB1 was detected by CLSM; the experimental results are shown in Fig.12 As shown, it can be seen that after R@L-MRS17(+) treatment, CRT was exposed to the cell membrane of dying tumor cells, and HMGB1 was released from the cell nucleus to the extracellular matrix, thereby enhancing the anti-tumor immune response.

[0110] Due to the leakage of cell contents mediated by pyroptosis, a large number of immunogenic cytokines, including LDH (D) and ATP (E), are also released outside the cells. These immunogenic factors will greatly activate the body's anti-tumor immunity. Fig.13 and Fig.14 As shown, pyroptosis activated after illumination triggers a strong immune response, releases DAMPs, activates maturation after DC uptake, and increases the expression of the phenotype CD80 of mature DC cells. In addition, the antigen presentation ability is enhanced, the antigen is effectively presented on the cell membrane surface, and the expression of MHC-II molecules is enhanced. This cascade of immune responses effectively activates the anti-tumor immune response, proving the strong immunogenicity of pyroptosis, effectively transforming breast cancer into a highly immunogenic "hot" tumor, which is conducive to further initiating an immune response.

[0111] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A liposome, characterized in that: The liposome comprises a liposome body encapsulating resiquimod and a polypeptide drug; the liposome body comprises a first lipid, a second lipid and a block copolymer, wherein; The first lipid is 1,2-dioleoyl phosphatidylcholine, egg yolk phosphatidylcholine, hydrogenated soybean phosphatidylcholine, dipalmitoyl phosphatidylcholine or dioleoyl Lα phosphatidylethanolamine; The second lipid is triglyceride, diglyceride or sterol; The block copolymer comprises a hydrophobic phospholipid and a hydrophilic long-chain polymer.

2. The liposome according to claim 1, characterized in that The mass ratio of the first lipid, the second lipid, the block copolymer and resiquimod is 20-30:1-5:1-5:1-5.

3. The liposome according to claim 1, characterized in that The polypeptide drug comprises at least one targeting chimeric peptide, wherein the targeting chimeric peptide comprises at least a CD47 targeting chimeric peptide having the following structural formula:

4. The liposome according to claim 1, characterized in that The hydrophobic phospholipid is distearyl phosphatidyl amide, and the hydrophilic long-chain polymer is poly (2-ethyl-2-oxazoline).

5. A method for preparing the liposome according to any one of claims 1 to 4, characterized in that: The method comprises the following steps: Step 1: dissolving the first lipid, the second lipid, the block copolymer and resiquimod in a first organic solution, obtaining a liposome film by rotary evaporation, and drying the liposome film; Step 2: adding water to the dried liposome film, hydrating at 60° C.-80° C. for 20-45 min, and then ultrasonicating and filtering to obtain a liposome body encapsulating resiquimod; Step 3: dissolving the polypeptide drug in a second organic solution to obtain an organic solution containing the polypeptide drug; Step 4: taking a portion of the organic solution containing the polypeptide drug, quickly dispersing it with water, and then dialyzing it to remove the second organic solution, and changing the water several times during the dialysis process to obtain an aqueous solution containing the polypeptide drug; Step 5: adding the liposome body encapsulating resiquimod into water and stirring, and at the same time adding the aqueous solution containing the polypeptide drug at a slow rate to obtain the liposome; Wherein, the first lipid is 1,2-dioleoyl phosphatidylcholine, egg yolk phosphatidylcholine, hydrogenated soybean phosphatidylcholine, dipalmitoyl phosphatidylcholine or dioleoyl Lα phosphatidylethanolamine; The second lipid is triglyceride, diglyceride or sterol; The block copolymer comprises a hydrophobic phospholipid and a hydrophilic long-chain polymer.

6. The method according to claim 5, characterized in that The method satisfies at least one of the following conditions: (1) The second lipid is cholesterol; (2) the mass ratio of the first lipid, the second lipid, the block copolymer and resiquimod is 20-30:1-5:1-5:1-5; (3) The polypeptide drug comprises at least one targeting chimeric peptide, wherein the targeting chimeric peptide comprises at least a CD47 targeting chimeric peptide having the following structural formula: (4) The hydrophobic phospholipid is distearyl phosphatidyl amide, and the hydrophilic long-chain polymer is poly (2-ethyl-2-oxazoline).

7. The method according to claim 6, characterized in that The mass ratio of the first lipid, the second lipid, the block copolymer and resiquimod is 22-28:2-3:2-3:2-4.

8. The method according to any one of claims 5 to 7, characterized in that: The method satisfies at least one of the following conditions: (1) The first organic solution is a mixed solution of chloroform and methanol; (2) the second organic solution is DMSO; (3) The mass ratio of resiquimod to the polypeptide drug is 0.5-3:1; (4) In step 2, the ultrasonic power is 80-120 mW, and the ultrasonic time is 3-6 min; (5) In step 2, filtering is performed by using a filter membrane with a pore size of 800 μm; (6) In step 4, dialysis is performed by using a dialysis bag with a dialysis molecular weight of 3500Da; the dialysis time is 18-36h; (7) In step 5, after all the aqueous solution containing the polypeptide drug is added, stirring is continued for 15-60 minutes to prepare the liposome.

9. A pharmaceutical preparation, characterized in that The pharmaceutical preparation comprises the liposome according to any one of claims 1 to 4, and one or more pharmaceutical excipients.

10. Use of the pharmaceutical preparation according to claim 9 or the liposome according to any one of claims 1 to 4 in the preparation of a drug for treating cancer; the cancer is non-small cell lung cancer, colon cancer, breast cancer, gastric cancer, esophageal cancer, prostate cancer, leukemia, head and neck cancer, pancreatic cancer, multiple myeloma or liver cancer.